KDIGO recommendations focused on diagnosis and treatment of CKD-MBD: Commented approach to clinical practice;KDIGO doporučení pro diagnostiku a léčbu CKD-MBD: Komentovaný návod pro klinickou praxi

Aktuality v Nefrologii

Volumn 16, Issue 4, 2010, Pages 113-126

  Sulková, Sylvie Dusilová ^a   Opatrná, Sylvie ^b   Ryšavá, Romana ^c   Tesař, Vladimír ^c   Teplan, Vladimír ^a   Viklický, Ondřej ^a   Zahálková, Jana ^d  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Středomoravská Nemocniční ^*  (Czech Republic)

Author keywords

Calcifications; Calcium; CKD MBD; Guidelines; Parathyroid hormone; Phosphate

Indexed keywords

BONE DISEASE; BONE MINERAL; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; REVIEW;

EID: 78651257343     PISSN: 1210955X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Adragao T, Pires A, Lucas C et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-1488. (Pubitemid 38786742)
2. Ambrus C, Molnar MZ, Czira ME et al. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients. Int Urol Nephrol 2009; 41: 1029-1038.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
4. Covic A, Kothawala P, Bernai M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009;24:1506-1523.
5. Floege J, Kim J, Ireland E et al. on behalf of ARO investigators: Serum iPTH, calcium and phosphate, and the risk of mortality in a European hemodialysis population. Nephrol Dial Transplant 2010; doi: 10.1093/ndt/gfq219.
6. Gauci C, Moranne O, Fouqueray B et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008;19:1592-1598.
7. Goldsmith DJA, Covic A, Fogue D et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; doi 10.1093/ndt/gfq513.
8. Goodman WG. Perspectives on renal bone disease. Kidney Int. 2006;70:S59-S63.
9. Goransson LG, Skadberg O, Bergrem H. Albumin-corrected or ionized calcium in renal failure? What to measure? Nephrol Dial Transplant 2005;20:2126-2129.
10. GRADE Working Group. Grade quality of evidence and strength of recommendations. BMJ. 2004;328:1490-149.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO® clinical practice guideline for the diagnosis, evaluation, preventive and treatment of chronic kidney disease - mineral bone disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113): S1-S130.
12. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740. (Pubitemid 37098542)
13. Manns BJ, Hodsman A, Zimmerman DL et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD): Am J Kidney Dis 2010;55:800-812.
14. Matias PJ, Jorge C, Ferreira C et al. Cholecalciferol supplementation in hemodialysis patients: effect on mineral metabolism, inflammation and cardiac dimension parameters. Clin J Am Soc Nephrol 2010;5:905-911.
15. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006;36:51-62. (Pubitemid 44050610)
16. Moe S, Drüeke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO®). Kidney Int 2006;69:1945-1953.
17. National Kidney Foundation. K/DOQITM clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3): S1-S201.
18. O'Neil WC: The fallacy of the calcium-phosphorus product. Kidney Int 2007;72:792-796.
19. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006:70:345-350. (Pubitemid 44086584)
20. Souberbielle JC, Cavalier E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for clinical laboratory? Clin Chem Lab Med 2010;48:769-774.
21. Souberbielle JC, Body JJ, Lappe JM et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev 2010; 11:709-15.
22. Toussaint ND, Pedagogos E, Beavis J et al. Improving CKD-MBD management in hemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant 2010; doi:10:1093/ndt/gfq602.
23. Uhlig K, MacLeod AM, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058-2065.
24. Uhlig K, Jeffrey B, Kestenbaum B et al. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55: 773-799.
25. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-1187. (Pubitemid 41623345)
26. Wald R, Tentori F, Tighiouart H et al. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Diasease in a large dialysis network. Am J Kidney Dis 2007; 49: 257-266.